Jan Grosser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan Grosser has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Donald P. Cameron
Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Laura Baranello
Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Anjana Shenoy
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2 shared publications - Georg Stoecklin
Division of Biochemistry, Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
2 shared publications - Johanna Schott
Mannheim Institute for Innate Immunoscience (MI3) and Mannheim Cancer Center (MCC), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications - Marius Bruer
Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2 shared publications
Latest Publications
- Open Access
- 18 October 2024
- Published by Karolinska Institutet
Topoisomerase regulation in the interplay between DNA transcription and replication
During DNA-involving processes such as transcription and replication the double helix is subjected to torsional stress. The over- or under-winding that encompasses torsional stress can be resolved by enzymes called topoisomerases. These enzymes cleave either one (Topoisomerase 1) or both (Topoisomerase 2) of the DNA strands, which allows for DNA relaxation, before resealing the break. Topoisomerase activity can be regulated by transcription or replication factors to fine-tune the efficiency of the genomic processes in which they are involved. Because cancers cells heavily rely on topoisomerases, these enzymes are common targets in cancer treatment.In this thesis, I have investigated topoisomerase regulation during transcription and replication, as well as new pharmacological strategies targeting the regulation of topoisomerase activity. The long-term goal of this thesis project is to develop approaches to selectively affect cancer cells viability. In paper 1, we focused on studying how the RNA polymerase 2 modulates Topoisomerase 1 during mitotic transcription. In paper 2, we investigated the mechanism of cellular adaptation to Topoisomerase 1 inhibitors. In paper 3, we developed a therapeutic approach that blocks the interaction between RNA polymerase 2 and Topoisomerase 1. We tested the strategy in preclinical models of pancreatic cancers. We showed that the treatment is effective and specific for the cancer cells and we have characterized the mechanism of cell killing.The thesis work integrates genomics, molecular biology, and drug screen methodologies, as well as preclinical mouse work done in collaboration. This works identifies Topoisomerase 1 as an important player in ensuring correct recruitment of various factors needed for transcription elongation, splicing and termination. The findings increase our understanding of regulatory pathways controlled by Topoisomerase 1 to protect DNA integrity and provide the rationale for the development of new approaches that target Topoisomerase 1 for cancer treatment.List of scientific papersI. "Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1" - Anika Wiegard, Vladislav Kuzin, Donald P. Cameron, Jan Grosser, Michele Ceribelli, Rashid Mehmood, Roberto Ballarino, Francesco Valant, Radoslaw Grochowski, Ivana Karabogdan, Nicola Crosetto, Arne Lindqvist, Anna Helene Bizard, Fedor Kouzine, Toyoaki Natsume, and Laura Baranello; Molecular Cell 81, 5007-5024.https://doi.org/10.1016/j.molcel.2021.10.015II. "NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors" - Alice Meroni, Jan Grosser, Sumedha Agashe, Natasha Ramakrishnan, Jessica Jackson, Priyanka Verma, Laura Baranello, Alessandro Vindigni; Sci. Adv. 8, eabq0648 (2022).https://doi.org/10.1126/sciadv.abq0648III. "Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription" - Donald P. Cameron*, Jan Grosser*, Swetlana Ladigan*, Vladislav Kuzin, Evanthia Iliopoulou, Anika Wiegard, Hajar Benredjem, Kathryn Jackson, Sven T. Liffers, Smiths Lueong, Phyllis F. Cheung, Deepak Vangala, Michael Pohl, Richard Viebahn, Christian Teschendorf, Heiner Wolters, Selami Usta, Keyi Geng, Claudia Kutter, Marie Arsenian-Henriksson, Jens T. Siveke, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Laura Baranello; Sci. Adv. 9, eadg5109 (2023).https://doi.org/10.1126/sciadv.adg5109
- 18 October 2024
- Published by Karolinska Institutet
Open AccessTopoisomerase regulation in the interplay between DNA transcription and replication
During DNA-involving processes such as transcription and replication the double helix is subjected to torsional stress. The over- or under-winding that encompasses torsional stress can be resolved by enzymes called topoisomerases. These enzymes cleave either one (Topoisomerase 1) or both (Topoisomerase 2) of the DNA strands, which allows for DNA relaxation, before resealing the break. Topoisomerase activity can be regulated by transcription or replication factors to fine-tune the efficiency of the genomic processes in which they are involved. Because cancers cells heavily rely on topoisomerases, these enzymes are common targets in cancer treatment.In this thesis, I have investigated topoisomerase regulation during transcription and replication, as well as new pharmacological strategies targeting the regulation of topoisomerase activity. The long-term goal of this thesis project is to develop approaches to selectively affect cancer cells viability. In paper 1, we focused on studying how the RNA polymerase 2 modulates Topoisomerase 1 during mitotic transcription. In paper 2, we investigated the mechanism of cellular adaptation to Topoisomerase 1 inhibitors. In paper 3, we developed a therapeutic approach that blocks the interaction between RNA polymerase 2 and Topoisomerase 1. We tested the strategy in preclinical models of pancreatic cancers. We showed that the treatment is effective and specific for the cancer cells and we have characterized the mechanism of cell killing.The thesis work integrates genomics, molecular biology, and drug screen methodologies, as well as preclinical mouse work done in collaboration. This works identifies Topoisomerase 1 as an important player in ensuring correct recruitment of various factors needed for transcription elongation, splicing and termination. The findings increase our understanding of regulatory pathways controlled by Topoisomerase 1 to protect DNA integrity and provide the rationale for the development of new approaches that target Topoisomerase 1 for cancer treatment.List of scientific papersI. "Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1" - Anika Wiegard, Vladislav Kuzin, Donald P. Cameron, Jan Grosser, Michele Ceribelli, Rashid Mehmood, Roberto Ballarino, Francesco Valant, Radoslaw Grochowski, Ivana Karabogdan, Nicola Crosetto, Arne Lindqvist, Anna Helene Bizard, Fedor Kouzine, Toyoaki Natsume, and Laura Baranello; Molecular Cell 81, 5007-5024.https://doi.org/10.1016/j.molcel.2021.10.015II. "NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors" - Alice Meroni, Jan Grosser, Sumedha Agashe, Natasha Ramakrishnan, Jessica Jackson, Priyanka Verma, Laura Baranello, Alessandro Vindigni; Sci. Adv. 8, eabq0648 (2022).https://doi.org/10.1126/sciadv.abq0648III. "Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription" - Donald P. Cameron*, Jan Grosser*, Swetlana Ladigan*, Vladislav Kuzin, Evanthia Iliopoulou, Anika Wiegard, Hajar Benredjem, Kathryn Jackson, Sven T. Liffers, Smiths Lueong, Phyllis F. Cheung, Deepak Vangala, Michael Pohl, Richard Viebahn, Christian Teschendorf, Heiner Wolters, Selami Usta, Keyi Geng, Claudia Kutter, Marie Arsenian-Henriksson, Jens T. Siveke, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Laura Baranello; Sci. Adv. 9, eadg5109 (2023).https://doi.org/10.1126/sciadv.adg5109
- Open Access
- 18 October 2024
- Published by Karolinska Institutet
Topoisomerase regulation in the interplay between DNA transcription and replication
During DNA-involving processes such as transcription and replication the double helix is subjected to torsional stress. The over- or under-winding that encompasses torsional stress can be resolved by enzymes called topoisomerases. These enzymes cleave either one (Topoisomerase 1) or both (Topoisomerase 2) of the DNA strands, which allows for DNA relaxation, before resealing the break. Topoisomerase activity can be regulated by transcription or replication factors to fine-tune the efficiency of the genomic processes in which they are involved. Because cancers cells heavily rely on topoisomerases, these enzymes are common targets in cancer treatment.In this thesis, I have investigated topoisomerase regulation during transcription and replication, as well as new pharmacological strategies targeting the regulation of topoisomerase activity. The long-term goal of this thesis project is to develop approaches to selectively affect cancer cells viability. In paper 1, we focused on studying how the RNA polymerase 2 modulates Topoisomerase 1 during mitotic transcription. In paper 2, we investigated the mechanism of cellular adaptation to Topoisomerase 1 inhibitors. In paper 3, we developed a therapeutic approach that blocks the interaction between RNA polymerase 2 and Topoisomerase 1. We tested the strategy in preclinical models of pancreatic cancers. We showed that the treatment is effective and specific for the cancer cells and we have characterized the mechanism of cell killing.The thesis work integrates genomics, molecular biology, and drug screen methodologies, as well as preclinical mouse work done in collaboration. This works identifies Topoisomerase 1 as an important player in ensuring correct recruitment of various factors needed for transcription elongation, splicing and termination. The findings increase our understanding of regulatory pathways controlled by Topoisomerase 1 to protect DNA integrity and provide the rationale for the development of new approaches that target Topoisomerase 1 for cancer treatment.List of scientific papersI. "Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1" - Anika Wiegard, Vladislav Kuzin, Donald P. Cameron, Jan Grosser, Michele Ceribelli, Rashid Mehmood, Roberto Ballarino, Francesco Valant, Radoslaw Grochowski, Ivana Karabogdan, Nicola Crosetto, Arne Lindqvist, Anna Helene Bizard, Fedor Kouzine, Toyoaki Natsume, and Laura Baranello; Molecular Cell 81, 5007-5024.https://doi.org/10.1016/j.molcel.2021.10.015II. "NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors" - Alice Meroni, Jan Grosser, Sumedha Agashe, Natasha Ramakrishnan, Jessica Jackson, Priyanka Verma, Laura Baranello, Alessandro Vindigni; Sci. Adv. 8, eabq0648 (2022).https://doi.org/10.1126/sciadv.abq0648III. "Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription" - Donald P. Cameron*, Jan Grosser*, Swetlana Ladigan*, Vladislav Kuzin, Evanthia Iliopoulou, Anika Wiegard, Hajar Benredjem, Kathryn Jackson, Sven T. Liffers, Smiths Lueong, Phyllis F. Cheung, Deepak Vangala, Michael Pohl, Richard Viebahn, Christian Teschendorf, Heiner Wolters, Selami Usta, Keyi Geng, Claudia Kutter, Marie Arsenian-Henriksson, Jens T. Siveke, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Laura Baranello; Sci. Adv. 9, eadg5109 (2023).https://doi.org/10.1126/sciadv.adg5109
- 18 October 2024
- Published by Karolinska Institutet
Open AccessTopoisomerase regulation in the interplay between DNA transcription and replication
During DNA-involving processes such as transcription and replication the double helix is subjected to torsional stress. The over- or under-winding that encompasses torsional stress can be resolved by enzymes called topoisomerases. These enzymes cleave either one (Topoisomerase 1) or both (Topoisomerase 2) of the DNA strands, which allows for DNA relaxation, before resealing the break. Topoisomerase activity can be regulated by transcription or replication factors to fine-tune the efficiency of the genomic processes in which they are involved. Because cancers cells heavily rely on topoisomerases, these enzymes are common targets in cancer treatment.In this thesis, I have investigated topoisomerase regulation during transcription and replication, as well as new pharmacological strategies targeting the regulation of topoisomerase activity. The long-term goal of this thesis project is to develop approaches to selectively affect cancer cells viability. In paper 1, we focused on studying how the RNA polymerase 2 modulates Topoisomerase 1 during mitotic transcription. In paper 2, we investigated the mechanism of cellular adaptation to Topoisomerase 1 inhibitors. In paper 3, we developed a therapeutic approach that blocks the interaction between RNA polymerase 2 and Topoisomerase 1. We tested the strategy in preclinical models of pancreatic cancers. We showed that the treatment is effective and specific for the cancer cells and we have characterized the mechanism of cell killing.The thesis work integrates genomics, molecular biology, and drug screen methodologies, as well as preclinical mouse work done in collaboration. This works identifies Topoisomerase 1 as an important player in ensuring correct recruitment of various factors needed for transcription elongation, splicing and termination. The findings increase our understanding of regulatory pathways controlled by Topoisomerase 1 to protect DNA integrity and provide the rationale for the development of new approaches that target Topoisomerase 1 for cancer treatment.List of scientific papersI. "Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1" - Anika Wiegard, Vladislav Kuzin, Donald P. Cameron, Jan Grosser, Michele Ceribelli, Rashid Mehmood, Roberto Ballarino, Francesco Valant, Radoslaw Grochowski, Ivana Karabogdan, Nicola Crosetto, Arne Lindqvist, Anna Helene Bizard, Fedor Kouzine, Toyoaki Natsume, and Laura Baranello; Molecular Cell 81, 5007-5024.https://doi.org/10.1016/j.molcel.2021.10.015II. "NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors" - Alice Meroni, Jan Grosser, Sumedha Agashe, Natasha Ramakrishnan, Jessica Jackson, Priyanka Verma, Laura Baranello, Alessandro Vindigni; Sci. Adv. 8, eabq0648 (2022).https://doi.org/10.1126/sciadv.abq0648III. "Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription" - Donald P. Cameron*, Jan Grosser*, Swetlana Ladigan*, Vladislav Kuzin, Evanthia Iliopoulou, Anika Wiegard, Hajar Benredjem, Kathryn Jackson, Sven T. Liffers, Smiths Lueong, Phyllis F. Cheung, Deepak Vangala, Michael Pohl, Richard Viebahn, Christian Teschendorf, Heiner Wolters, Selami Usta, Keyi Geng, Claudia Kutter, Marie Arsenian-Henriksson, Jens T. Siveke, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Laura Baranello; Sci. Adv. 9, eadg5109 (2023).https://doi.org/10.1126/sciadv.adg5109
- Open Access
- 13 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (41) , eadg5109
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription
Pancreatic carcinoma lacks effective therapeutic strategies resulting in poor prognosis. Transcriptional dysregulation due to alterations in KRAS and MYC affects initiation, development, and survival of this tumor type. Using patient-derived xenografts of KRAS- and MYC-driven pancreatic carcinoma, we show that coinhibition of topoisomerase 1 (TOP1) and bromodomain-containing protein 4 (BRD4) synergistically induces tumor regression by targeting promoter pause release. Comparing the nascent transcriptome with the recruitment of elongation and termination factors, we found that coinhibition of TOP1 and BRD4 disrupts recruitment of transcription termination factors. Thus, RNA polymerases transcribe downstream of genes for hundreds of kilobases leading to readthrough transcription. This occurs during replication, perturbing replisome progression and inducing DNA damage. The synergistic effect of TOP1 + BRD4 inhibition is specific to cancer cells leaving normal cells unaffected, highlighting the tumor’s vulnerability to transcriptional defects. This preclinical study provides a mechanistic understanding of the benefit of combining TOP1 and BRD4 inhibitors to treat pancreatic carcinomas addicted to oncogenic drivers of transcription and replication.
- 13 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (41) , eadg5109
Open AccessCoinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription
Pancreatic carcinoma lacks effective therapeutic strategies resulting in poor prognosis. Transcriptional dysregulation due to alterations in KRAS and MYC affects initiation, development, and survival of this tumor type. Using patient-derived xenografts of KRAS- and MYC-driven pancreatic carcinoma, we show that coinhibition of topoisomerase 1 (TOP1) and bromodomain-containing protein 4 (BRD4) synergistically induces tumor regression by targeting promoter pause release. Comparing the nascent transcriptome with the recruitment of elongation and termination factors, we found that coinhibition of TOP1 and BRD4 disrupts recruitment of transcription termination factors. Thus, RNA polymerases transcribe downstream of genes for hundreds of kilobases leading to readthrough transcription. This occurs during replication, perturbing replisome progression and inducing DNA damage. The synergistic effect of TOP1 + BRD4 inhibition is specific to cancer cells leaving normal cells unaffected, highlighting the tumor’s vulnerability to transcriptional defects. This preclinical study provides a mechanistic understanding of the benefit of combining TOP1 and BRD4 inhibitors to treat pancreatic carcinomas addicted to oncogenic drivers of transcription and replication.
- 19 January 2023
- Published by Springer Nature in Nature Methods
- Vol. 20 (2) , 316
Publisher Correction: Nascent Ribo-Seq measures ribosomal loading time and reveals kinetic impact on ribosome density
- 19 January 2023
- Published by Springer Nature in Nature Methods
- Vol. 20 (2) , 316
Publisher Correction: Nascent Ribo-Seq measures ribosomal loading time and reveals kinetic impact on ribosome density
- Open Access
- 9 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (49) , eabq0648
NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors
DNA topoisomerase 1 (TOP1) inhibitors are mainstays of anticancer therapy. These drugs trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of TOP1-ccs perturbs DNA replication fork progression, leading to DNA breaks and cell death. By analyzing the genomic occupancy and activity of TOP1, we show that cells adapt to treatment with multiple doses of TOP1 inhibitor by promoting the degradation of TOP1-ccs, allowing cells to better tolerate subsequent doses of TOP1 inhibitor. The E3-RING Cullin 3 ligase in complex with the BTBD1 and BTBD2 adaptor proteins promotes TOP1-cc ubiquitination and subsequent proteasomal degradation. NEDDylation of Cullin 3 activates this pathway, and inhibition of protein NEDDylation or depletion of Cullin 3 sensitizes cancer cells to TOP1 inhibitors. Collectively, our data uncover a previously unidentified NEDD8–Cullin 3 pathway involved in the adaptive response to TOP1 inhibitors, which can be targeted to improve the efficacy of TOP1 drugs in cancer therapy.
- 9 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (49) , eabq0648
Open AccessNEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors
DNA topoisomerase 1 (TOP1) inhibitors are mainstays of anticancer therapy. These drugs trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of TOP1-ccs perturbs DNA replication fork progression, leading to DNA breaks and cell death. By analyzing the genomic occupancy and activity of TOP1, we show that cells adapt to treatment with multiple doses of TOP1 inhibitor by promoting the degradation of TOP1-ccs, allowing cells to better tolerate subsequent doses of TOP1 inhibitor. The E3-RING Cullin 3 ligase in complex with the BTBD1 and BTBD2 adaptor proteins promotes TOP1-cc ubiquitination and subsequent proteasomal degradation. NEDDylation of Cullin 3 activates this pathway, and inhibition of protein NEDDylation or depletion of Cullin 3 sensitizes cancer cells to TOP1 inhibitors. Collectively, our data uncover a previously unidentified NEDD8–Cullin 3 pathway involved in the adaptive response to TOP1 inhibitors, which can be targeted to improve the efficacy of TOP1 drugs in cancer therapy.
- Open Access
- 1 December 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 5007-5024.e9
Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1
- 1 December 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 5007-5024.e9
Open AccessTopoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1
- Open Access
- 9 September 2021
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (9) , e1009763
Deficiency of Polη in Saccharomyces cerevisiae reveals the impact of transcription on damage-induced cohesion
The structural maintenance of chromosome (SMC) complex cohesin mediates sister chromatid cohesion established during replication, and damage-induced cohesion formed in response to DSBs post-replication. The translesion synthesis polymerase Polη is required for damage-induced cohesion through a hitherto unknown mechanism. Since Polη is functionally associated with transcription, and transcription triggers de novo cohesion in Schizosaccharomyces pombe, we hypothesized that transcription facilitates damage-induced cohesion in Saccharomyces cerevisiae. Here, we show dysregulated transcriptional profiles in the Polη null mutant (rad30Δ), where genes involved in chromatin assembly and positive transcription regulation were downregulated. In addition, chromatin association of RNA polymerase II was reduced at promoters and coding regions in rad30Δ compared to WT cells, while occupancy of the H2A.Z variant (Htz1) at promoters was increased in rad30Δ cells. Perturbing histone exchange at promoters inactivated damage-induced cohesion, similarly to deletion of the RAD30 gene. Conversely, altering regulation of transcription elongation suppressed the deficient damage-induced cohesion in rad30Δ cells. Furthermore, transcription inhibition negatively affected formation of damage-induced cohesion. These results indicate that the transcriptional deregulation of the Polη null mutant is connected with its reduced capacity to establish damage-induced cohesion. This also suggests a linkage between regulation of transcription and formation of damage-induced cohesion after replication.
- 9 September 2021
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (9) , e1009763
Open AccessDeficiency of Polη in Saccharomyces cerevisiae reveals the impact of transcription on damage-induced cohesion
The structural maintenance of chromosome (SMC) complex cohesin mediates sister chromatid cohesion established during replication, and damage-induced cohesion formed in response to DSBs post-replication. The translesion synthesis polymerase Polη is required for damage-induced cohesion through a hitherto unknown mechanism. Since Polη is functionally associated with transcription, and transcription triggers de novo cohesion in Schizosaccharomyces pombe, we hypothesized that transcription facilitates damage-induced cohesion in Saccharomyces cerevisiae. Here, we show dysregulated transcriptional profiles in the Polη null mutant (rad30Δ), where genes involved in chromatin assembly and positive transcription regulation were downregulated. In addition, chromatin association of RNA polymerase II was reduced at promoters and coding regions in rad30Δ compared to WT cells, while occupancy of the H2A.Z variant (Htz1) at promoters was increased in rad30Δ cells. Perturbing histone exchange at promoters inactivated damage-induced cohesion, similarly to deletion of the RAD30 gene. Conversely, altering regulation of transcription elongation suppressed the deficient damage-induced cohesion in rad30Δ cells. Furthermore, transcription inhibition negatively affected formation of damage-induced cohesion. These results indicate that the transcriptional deregulation of the Polη null mutant is connected with its reduced capacity to establish damage-induced cohesion. This also suggests a linkage between regulation of transcription and formation of damage-induced cohesion after replication.
- 3 September 2021
- Published by Springer Nature in Nature Methods
- Vol. 18 (9) , 1068-1074
Nascent Ribo-Seq measures ribosomal loading time and reveals kinetic impact on ribosome density
In general, mRNAs are assumed to be loaded with ribosomes instantly upon entry into the cytoplasm. To measure ribosome density (RD) on nascent mRNA, we developed nascent Ribo-Seq by combining Ribo-Seq with progressive 4-thiouridine labeling. In mouse macrophages, we determined experimentally the lag between the appearance of nascent mRNA and its association with ribosomes, which was calculated to be 20–22 min for bulk mRNA. In mouse embryonic stem cells, nRibo-Seq revealed an even stronger lag of 35–38 min in ribosome loading. After stimulation of macrophages with lipopolysaccharide, the lag between cytoplasmic and translated mRNA leads to uncoupling between input and ribosome-protected fragments, which gives rise to distorted RD measurements under conditions where mRNA amounts are far from steady-state expression. As a result, we demonstrate that transcriptional changes affect RD in a passive way.
- 3 September 2021
- Published by Springer Nature in Nature Methods
- Vol. 18 (9) , 1068-1074
Nascent Ribo-Seq measures ribosomal loading time and reveals kinetic impact on ribosome density
In general, mRNAs are assumed to be loaded with ribosomes instantly upon entry into the cytoplasm. To measure ribosome density (RD) on nascent mRNA, we developed nascent Ribo-Seq by combining Ribo-Seq with progressive 4-thiouridine labeling. In mouse macrophages, we determined experimentally the lag between the appearance of nascent mRNA and its association with ribosomes, which was calculated to be 20–22 min for bulk mRNA. In mouse embryonic stem cells, nRibo-Seq revealed an even stronger lag of 35–38 min in ribosome loading. After stimulation of macrophages with lipopolysaccharide, the lag between cytoplasmic and translated mRNA leads to uncoupling between input and ribosome-protected fragments, which gives rise to distorted RD measurements under conditions where mRNA amounts are far from steady-state expression. As a result, we demonstrate that transcriptional changes affect RD in a passive way.